XOMA logo

XOMANASDAQ: XOMA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

06 June 1986

Next earnings report:

07 March 2025

Last dividends:

02 April 2024

Next dividends:

N/A
$355.96 M
-3%vs. 3y high
61%vs. sector
-vs. 3y high
-vs. sector
-vs. 3y high
-vs. sector
-50%vs. 3y high
90%vs. sector

Price

after hours | Fri, 15 Nov 2024 21:02:24 GMT
$30.21+$0.33(+1.10%)
$734.00 K$8.65 M

Analysts recommendations

Institutional Ownership

XOMA Latest News

What Makes XOMA Royalty (XOMA) a New Buy Stock
zacks.com11 November 2024 Sentiment: POSITIVE

XOMA Royalty (XOMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates
zacks.com07 November 2024 Sentiment: POSITIVE

XOMA Royalty (XOMA) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.60 per share a year ago.

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
globenewswire.com22 October 2024 Sentiment: POSITIVE

XOMA Royalty has acquired 50 percent of Twist's existing royalty and milestone economics for $15 million XOMA Royalty's portfolio now holds over 100 assets ranging from revenue-generating commercial therapeutics to pre-clinical programs EMERYVILLE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) announced today it has entered into a $15 million royalty monetization arrangement with Twist Bioscience Corporation to acquire a 50 percent economic interest in all future milestones and royalties associated with the 60-plus partnered early-stage programs across 30 partners enabled by Twist Bioscience's Biopharma Solutions business unit.

XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties
seekingalpha.com15 October 2024 Sentiment: POSITIVE

XOMA Royalty Corporation offers diversified revenue streams from milestone and royalty rights in various therapeutic areas, providing stable returns with lower clinical trial risks. The company's preferred shares, XOMAP and XOMAO, offer high, reliable dividends, making them attractive for income investors seeking biotech exposure. XOMA's robust financials, including substantial cash reserves and non-dilutive financing, ensure the sustainability of dividend payments for many years.

XOMA Stock Dips Amidst Biotech Sector Decline
gurufocus.com03 October 2024 Sentiment: NEGATIVE

XOMA (XOMA, Financial), a company engaged in biotechnology royalties, saw its stock price plummet by 5.36%, with the latest price reported at $25.91. The trading volume reached 3,638 shares, representing a turnover rate of 0.03% and a price fluctuation amplitude of 3.79%.

XOMA Royalty Declares Quarterly Preferred Stock Dividends
globenewswire.com23 September 2024 Sentiment: POSITIVE

EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share.

XOMA Royalty to Present at Upcoming Investor Conferences in September
globenewswire.com04 September 2024 Sentiment: POSITIVE

EMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following September 2024 investor conferences:

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
globenewswire.com13 August 2024 Sentiment: POSITIVE

Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from  Day One Pharmaceuticals and Rezolute

Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains?
zacks.com18 July 2024 Sentiment: POSITIVE

Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares
seekingalpha.com29 June 2024 Sentiment: POSITIVE

XOMA Corporation operates as a biotechnology royalty aggregator, acquiring economic rights to milestones and royalties from approved or clinical-stage drugs. XOMA's diverse IP portfolio spans various therapeutic areas, including oncology, immunology, rare diseases, and acute pain, mitigating investment risks. The recent acquisition of Kinnate Biopharma extends XOMA's portfolio into oncology despite Kinnate selling its crown jewel, exarafenib, before the acquisition.

What type of business is XOMA?

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

What sector is XOMA in?

XOMA is in the Healthcare sector

What industry is XOMA in?

XOMA is in the Biotechnology industry

What country is XOMA from?

XOMA is headquartered in United States

When did XOMA go public?

XOMA initial public offering (IPO) was on 06 June 1986

What is XOMA website?

https://xoma.com

Is XOMA in the S&P 500?

No, XOMA is not included in the S&P 500 index

Is XOMA in the NASDAQ 100?

No, XOMA is not included in the NASDAQ 100 index

Is XOMA in the Dow Jones?

No, XOMA is not included in the Dow Jones index

When was XOMA the previous earnings report?

No data

When does XOMA earnings report?

The next expected earnings date for XOMA is 07 March 2025